-
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform
-
Agreement provides for Parabilis to receive$125MfromRegeneron, consisting of a$50Mupfront payment and$75Mequity commitment, with up to approximately$2.2Bin additional potential milestone payments plus tiered royalties
TARRYTOWN, N.Y.,May 18, 2026(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets.
Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited to traditional small molecule binding. The collaboration is designed to explore the use of Helicons both as stand-alone therapies and as part of AHCs.
“This collaboration reflects Regeneron’s approach of advancing cutting-edge and diversified science to produce a robust portfolio of innovative medicines for patients in need,” saidGeorge D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer ofRegeneron. “In addition to the potential of Helicons to address previously undruggable targets, the collaboration’s intent to couple Helicons to our VelocImmune® derived-antibodies so as to precisely deliver them to cells of interest represents an exciting new approach with the potential to create an entirely new therapeutic class that can span multiple therapeutic areas.”
Antibody–drug conjugates traditionally use antibodies to selectively deliver drug payloads into target cells to drive cell death from within. The AHCs envisioned by this collaboration are underpinned by the same delivery principle: pairing antibody-targeted cell access with Helicon payloads designed to selectively modulate specific intracellular proteins, including some long considered undruggable.
Under the terms of the agreement, Parabilis is to receive$125 millionfromRegeneronin the form of a$50 millionupfront payment and a commitment to invest$75 millionin Parabilis’ next equity financing, subject to certain conditions. Parabilis is also eligible to receive milestone payments for development, regulatory and commercial milestones, as well as tiered royalties up to the low double-digits on future net sales of any approved medicines resulting from the collaboration. With five initial targets, the agreement provides the potential for up to approximately$2.2 billionin total milestone payments to Parabilis. Under the terms of the agreement, additional targets may be pursued upon additional option payments fromRegeneron.
The agreement provides for the parties to collaborate to discover new Helicons and AHCs, whichRegeneronwill then be responsible for advancing through development, manufacturing and worldwide commercialization.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using its proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.